ClinicalTrials.gg
CompletedNCT01425359TERISAUpdated Nov 4, 2014Results posted

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

A Phase 4 interventional study of Ranolazine and Ranolazine placebo in Angina Pectoris, Coronary Artery Disease and Type 2 Diabetes Mellitus, sponsored by Gilead Sciences. Completed at 135 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-04.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
949
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing ranolazine in Angina Pectoris — none open to participants now, none under way, none of them phase 3. Ranolazine · Angina Pectoris.

Enrollment
3rd of 14
949 · median 44
Started
2011
with 3 others
Phase 4
5 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
5 of 14
Gilead Sciences

Among the 14 studies testing ranolazine in Angina Pectoris, this one is the 3rd largest by enrollment, is one of 4 that started in 2011, is one of 5 in phase 4, and was the 7th registered.

Angina Pectoris

454 studies on the registry are indexed under Angina Pectoris; 68 are open to participants now.

Browse Angina Pectoris studies →

Open to participants now

None of the 14 studies testing ranolazine in Angina Pectoris is open now. The open studies under Angina Pectoris, anywhere →

About ranolazine

Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Angina Pectoris studies recruiting now, 35 (74%) set no upper age limit and 1 (2%) stops at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing ranolazine in Angina Pectoris as a file.
02

Study summary

This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus (T2DM), and whether ranolazine can reduce the frequency of angina (chest pain) attacks, compared to a placebo. Subjects will be asked to record their daily angina episodes in a diary at the end of each study day. Ranolazine is approved for the treatment of chronic angina, and is not approved for the treatment of T2DM.

Read the detailed description

Participants who meet the eligibility criteria at screening will enter a 4-to 6-week Qualifying Period. The allowed concomitant antianginal medication(s) must be maintained at a stable dose throughout the study. Participants will document the number of angina episodes, number of sublingual nitroglycerin doses taken, and a dyspnea score (on a scale from 1 to 5) on a daily basis in a diary. Participants eligible to stay in the study after the Qualifying Period will enter the 8-week double-blind dosing phase. Participants will have study visits at the end of Weeks 2 and 8. Participants will continue to document the number of angina episodes and number of sublingual nitroglycerin doses taken as well as a dyspnea score on a daily basis by the end of each day in their diary. In addition, participants will be called during Week 2 and at the end of Week 5 to encourage compliance. A safety follow-up phone call will be made 14 days after the last study visit or early discontinuation.

03

Conditions studied

  • Angina Pectoris
  • Coronary Artery Disease
  • Type 2 Diabetes Mellitus

Keywords

  • Chronic angina
  • Angina pectoris
  • Coronary artery disease
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Males and females aged at least 18 years
  • At least a 3-month history of chronic stable angina triggered by physical effort and relieved by rest and/or sublingual nitroglycerin
  • CAD documented by one or more of the following:

    1. Angiographic evidence of ≥ 50% stenosis of one or more major coronary arteries
    2. History of myocardial infarction (MI) documented by positive myocardial muscle creatine kinase (CK-MB) enzymes, troponins, or (ECG) changes
    3. Cardiac imaging study or exercise test diagnostic for CAD
  • Treatment with up to 2 antianginal therapies at a stable dose for at least 2 weeks prior to the Qualifying Period.
  • Documented history of T2DM
  • Willing to maintain stable tobacco usage habits throughout the study
  • Willing to maintain stable activity levels throughout the study
  • Females of must agree to utilize highly effective methods from Screening throughout the duration of study treatment and for 14 days following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • (NYHA) Class III and IV
  • Acute coronary syndrome in the prior 2 months or planned coronary revascularization during the study period
  • Stroke or within 6 months prior to Screening
  • > 500 milliseconds
  • Uncontrolled hypertension (seated systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg)
  • Systolic blood pressure \< 100 mmHg
  • hepatic impairment
  • Prior treatment with ranolazine, or known or intolerance to ranolazine
  • Females who are breastfeeding
  • Positive serum pregnancy test
  • Participation in another drug or device study within 1 month prior to Screening
  • Current treatment with trimetazidine, ivabradine, or nicorandil. Subjects will need to discontinue these medications 2 weeks prior to the Qualifying Period.
  • Current treatment with potent inhibitors of cytochrome (CYP)3A (eg, ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir)
  • Current treatment with and P glycoprotein (Pgp) inducers (eg, rifampicin/rifampin, carbamazepine, and St. John's wort [Hypericum perforatum])
  • Current treatment with CYP3A4 substrates with a narrow therapeutic range (eg, cyclosporine, tacrolimus, and sirolimus)
  • Subjects taking simvastatin who cannot reduce the dose to 20 mg once daily or who cannot switch to another statin
  • Current treatment with Class I or III antiarrhythmic medications
  • History of illicit drug use or alcohol abuse within 1 year of Screening
  • Any other conditions that, in the opinion of the investigator, are likely to prevent compliance with the study protocol or pose a safety concern if the subject participates in the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
949 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period. Treatment Period: Placebo to match ranolazine (Day 1: 1 tablet in the evening; Days 2-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 8 weeks.

    Drug: Ranolazine placebo

  • Experimental
    Ranolazine

    Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period. Treatment period: Ranolazine tablets (Day 1: 1 × 500 tablet in the evening; Days 2-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 8 weeks.

    Drug: Ranolazine · Drug: Ranolazine placebo

Interventions

  • Also known as: Ranexa®

  • DrugRanolazine placebo
06

What researchers measure

Primary outcomes

  1. Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment

    Average weekly angina frequency was defined as the total number of angina episodes reported during the last 6 weeks of treatment divided by 6 weeks. For subjects who terminated with less than 6 weeks of treatment, frequency was calculated as the total number of angina episodes reported during the treatment period divided by the subject's actual duration of treatment.

    Time frame: 6 weeks

Secondary outcomes

  1. Average Weekly Frequency of Sublingual Nitroglycerin Use Over the Last 6 Weeks of Treatment

    Average weekly frequency of sublingual nitroglycerin use was defined as the total number reported during the last 6 weeks of treatment divided by the duration corresponding to the last 6 weeks of treatment.

    Time frame: 6 weeks

  2. Percentage of Weeks Participants Achieved at Least a 50% Reduction in Angina Frequency

    For each participant, the percentage of the last 6 weeks on treatment during which the angina frequency was less than or equal to 50% of the baseline average weekly angina frequency was determined.

    Time frame: 6 weeks

  3. Percentage of the Last 6 Weeks on Treatment During Which the Angina Frequency Was ≤ 50% of the Baseline Average Weekly Angina Frequency

    Time frame: 6 weeks

  4. Change From Baseline in the Short-Form 36® (SF-36) Mental and Physical Component Scores

    The range of each health domain score is 0-100, with 0 indicating a poorer health state and 100 indicating a better health state. An increase in score indicates an improvement in health state. Participants were asked to complete the survey at randomization (prior to receiving treatment), and at end of treatment visit (Week 8) or early study drug discontinuation or early termination visit. The survey asked participants for responses specific to the preceding 4 weeks prior to completing the survey.

    Time frame: Up to 8 weeks

  5. Patient's Global Impression of Change (PGIC) Scale Score

    The PGIC was completed at the end of treatment/last visit.The PGIC scale measures the change in the participant's overall status since the beginning of the study on a scale ranging from 1 (no change or worse) to 7 (very much improved).

    Time frame: 8 weeks

07

Results

Posted Nov 4, 2014

Participant flow

Participants were enrolled at a total of 116 study sites in North America, Europe, and Asia. The first participant was screened on 05 October 2011. The last participant observation occurred on 25 October 2012.

Participant flow — Overall Study
MilestonePlaceboRanolazine
Started476473
Completed457451
Not completed1922
Withdrew: Randomized but not treated23
Withdrew: Adverse event98
Withdrew: Revascularization01
Withdrew: Death01
Withdrew: Unsatisfactory response10
Withdrew: Protocol violation12
Withdrew: Subject withdrew consent12
Withdrew: Investigator's discretion20
Withdrew: Did not meet qualifying criteria35

Outcome measures

PrimaryAverage Weekly Angina Frequency Over the Last 6 Weeks of Treatment

Average weekly angina frequency was defined as the total number of angina episodes reported during the last 6 weeks of treatment divided by 6 weeks. For subjects who terminated with less than 6 weeks of treatment, frequency was calculated as the total number of angina episodes reported during the treatment period divided by the subject's actual duration of treatment.

Time frame:
6 weeks
Reported as:
Mean · angina attacks per week
Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment
angina attacks per weekPlaceboRanolazine
Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment5.2 ± 4.734.5 ± 4.32
Statistical analysis
  • Placebo vs Ranolazine · Generalized linear model · p = 0.008 (Angina frequency was compared by fitting a generalized linear model with log link and negative binomial distribution response.)
SecondaryAverage Weekly Frequency of Sublingual Nitroglycerin Use Over the Last 6 Weeks of Treatment

Average weekly frequency of sublingual nitroglycerin use was defined as the total number reported during the last 6 weeks of treatment divided by the duration corresponding to the last 6 weeks of treatment.

Time frame:
6 weeks
Reported as:
Mean · nitroglycerin uses per week
Average Weekly Frequency of Sublingual Nitroglycerin Use Over the Last 6 Weeks of Treatment
nitroglycerin uses per weekPlaceboRanolazine
Average Weekly Frequency of Sublingual Nitroglycerin Use Over the Last 6 Weeks of Treatment3.6 ± 5.352.9 ± 4.34
Statistical analysis
  • Placebo vs Ranolazine · Generalized linear model · p = 0.003 (Sublingual nitroglycerin use frequency was compared by fitting a generalized linear model with log link and negative binomial distribution response.)
SecondaryPercentage of Weeks Participants Achieved at Least a 50% Reduction in Angina Frequency

For each participant, the percentage of the last 6 weeks on treatment during which the angina frequency was less than or equal to 50% of the baseline average weekly angina frequency was determined.

Time frame:
6 weeks
Reported as:
Mean · percentage of weeks
Percentage of Weeks Participants Achieved at Least a 50% Reduction in Angina Frequency
percentage of weeksPlaceboRanolazine
Percentage of Weeks Participants Achieved at Least a 50% Reduction in Angina Frequency41 ± 3646 ± 35
SecondaryPercentage of the Last 6 Weeks on Treatment During Which the Angina Frequency Was ≤ 50% of the Baseline Average Weekly Angina Frequency
Time frame:
6 weeks
Reported as:
Mean · percentage of weeks
Percentage of the Last 6 Weeks on Treatment During Which the Angina Frequency Was ≤ 50% of the Baseline Average Weekly Angina Frequency
percentage of weeksPlaceboRanolazine
Percentage of the Last 6 Weeks on Treatment During Which the Angina Frequency Was ≤ 50% of the Baseline Average Weekly Angina Frequency50 ± 1.454 ± 1.3
SecondaryChange From Baseline in the Short-Form 36® (SF-36) Mental and Physical Component Scores

The range of each health domain score is 0-100, with 0 indicating a poorer health state and 100 indicating a better health state. An increase in score indicates an improvement in health state. Participants were asked to complete the survey at randomization (prior to receiving treatment), and at end of treatment visit (Week 8) or early study drug discontinuation or early termination visit. The survey asked participants for responses specific to the preceding 4 weeks prior to completing the survey.

Time frame:
Up to 8 weeks
Reported as:
Mean · units on a scale
Change From Baseline in the Short-Form 36® (SF-36) Mental and Physical Component Scores
units on a scalePlaceboQualifying Phase: Participants Entered a 2-week Washout Period
Mental Component Score1.2 ± 0.371.0 ± 0.39
Physical Component Score1.9 ± 0.252.8 ± 0.26
SecondaryPatient's Global Impression of Change (PGIC) Scale Score

The PGIC was completed at the end of treatment/last visit.The PGIC scale measures the change in the participant's overall status since the beginning of the study on a scale ranging from 1 (no change or worse) to 7 (very much improved).

Time frame:
8 weeks
Reported as:
Mean · units on a scale
Patient's Global Impression of Change (PGIC) Scale Score
units on a scalePlaceboRanolazine
Patient's Global Impression of Change (PGIC) Scale Score3.9 ± 0.074.0 ± 0.07

Adverse events

Collected over Baseline to Day 56 plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—20/474 (4.2%)0/474 (0%)
Ranolazine—16/470 (3.4%)0/470 (0%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPlaceboRanolazine
Angina unstableCardiac disorders1/4743/470
Acute myocardial infarctionCardiac disorders3/4742/470
Atrial fibrillationCardiac disorders3/4740/470
Ischaemic strokeNervous system disorders3/4741/470
Chest painGeneral disorders1/4742/470
Cardiac failure acuteCardiac disorders2/4740/470
Angina pectorisCardiac disorders1/4741/470
Cardiac failure chronicCardiac disorders0/4741/470
Cardiogenic shockCardiac disorders0/4741/470
Ventricular tachycardiaCardiac disorders0/4741/470

Baseline characteristics

Safety Analysis Set: randomized participants who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(years)PlaceboRanolazineTotal
Mean64 ± 8.563 ± 8.664 ± 8.5
Age, Customized
Age, Customized(participants)PlaceboRanolazineTotal
< 65 years249264513
65 - 74 years170160330
≥ 75 years5546101
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRanolazineTotal
Female182180362
Male292290582
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboRanolazineTotal
Asian112
Black or African American257
White471464935
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboRanolazineTotal
Hispanic or Latino549
Not Hispanic or Latino464462926
Not Reported336
Unknown213
Region of Enrollment
Region of Enrollment(participants)PlaceboRanolazineTotal
United States121527
Belarus101
Serbia325
Slovenia011
Slovakia12921
Ukraine5369122
Israel101424
Russian Federation281263544
Czech Republic369
Canada213
Poland534093
Bulgaria91120
Georgia364076
Germany123
Body Mass Index
Body Mass Index(kg/m^2)PlaceboRanolazineTotal
Mean31.1 ± 4.9031.3 ± 5.0131.2 ± 4.96
Glycosylated hemoglobin (HbA1c)
Glycosylated hemoglobin (HbA1c)(percent HbA1c in blood)PlaceboRanolazineTotal
Mean7.3 ± 1.537.3 ± 1.507.3 ± 1.52
08

Study locations

135 sites
  • Cardiology and Medicine Clinic
    Little Rock, Arkansas 72204, United States
  • Merced Heart Associates
    Merced, California 95340, United States
  • Spectrum Clinical Research Institute, Inc
    Moreno Valley, California 92553, United States
  • Sacramento Heart and Vascular Research Center
    Sacramento, California 95825, United States
  • South Florida Research Solutions, LLC
    Hollywood, Florida 33021, United States
  • Baptist Heart Specialist
    Jacksonville, Florida 32207, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida 33880, United States
  • Masters of Clinical Research, Inc.
    Augusta, Georgia 30909, United States
  • Columbus Cardiology Associates
    Columbus, Georgia 31909, United States
  • Central Cardiology Associates
    Elizabethtown, Kentucky 42701, United States
  • Research Integrity, LLC
    Owensboro, Kentucky 42303, United States
  • Alexandria Cardiology Clinic
    Alexandria, Louisiana 71301, United States
  • Clinical Trials Management, LLC
    Mandeville, Louisiana 70471, United States
  • Endeavor Medical Research, PLC
    Alpena, Michigan 49707, United States
  • Minneapolis Heart Institute Foundation
    Minneapolis, Minnesota 55407, United States
  • Cross Country Cardiology
    Edgewater, New Jersey 07020, United States
  • Kore CV Research
    Jackson, Tennessee 38305, United States
  • Wellmont Cardiovascular Associates Heart Institute
    Johnson City, Tennessee 37604, United States
  • Med-Tech Research
    Houston, Texas 77024, United States
  • Humble Cardiology Associates
    Humble, Texas 77338, United States
  • State Institution "Gomel regional clinical hospital"
    Gomel, 246029, Belarus
  • State Inst Rep Scientific and Practical center
    Minsk, 220036, Belarus
  • Diagnostic Consultative Center, Ascendent Cardiological Out-Patient Office
    Sofia, 1202, Bulgaria
  • MHAT "Tsar Boris III"
    Sofia, 1233, Bulgaria
  • National Cardiology Center, Cardiology Clinic - III
    Sofia, 1309, Bulgaria
  • MHAT "Vita", Cardiology Department
    Sofia, 1505, Bulgaria
  • UMHAT "Tsaritsa Yoanna" - ISUL, Cardiology Clinic
    Sofia, 1527, Bulgaria
  • Military Medical Academy, Clinic of Cardiology and Intesive Care
    Sofia, 1606, Bulgaria
  • SKDS Research Inc
    New Market, Ontario L3Y 5G8, Canada
  • Dr. Roger Labonté Professional Medicine Corp.
    Sudbury, Ontario P3E 3B8, Canada
  • Aniol Gupta MD
    Toronto, Ontario M9V 4B4, Canada
  • Montréal General Hospital
    Montreal, Quebec H3G 1A4, Canada
  • High Desert Medical Group
    Lancaster, 93534, Canada
  • Montreal Heart Institute
    Montreal, H1T 1C8, Canada
  • London Road Diagnostic Clinic and Medical Centre
    Ontario, N7T 4X3, Canada
  • Topsail Road Medical Clinic
    Saint John's, A1E 2E2, Canada
  • Vojenska Nemocnice Brno
    Brno, 636 00, Czech Republic
  • Cardiocentrum Kladno s.r.o.
    Kladno, 27280, Czech Republic
  • Poliklinika Modrany - Kardiologie
    Praha 4, 14300, Czech Republic
  • Fakultní Nemocnice v Motole
    Praha 5, 150 06, Czech Republic
  • Corintez s.r.o.
    Praha 5, 158 00, Czech Republic
  • Centrum klinického výzkumu, s.r.o.
    Príbram, 26101, Czech Republic
  • Nemocnice Slaný
    Slaný, 27401, Czech Republic
  • Tbilisi State Medical University Alexandre Aladashvili University Clinic
    Tbilisi, 0102, Georgia
  • Amtel Hospital First Clinical LLC
    Tbilisi, 0144, Georgia
  • Clinic "Guli"
    Tbilisi, 0144, Georgia
  • Cardio-Reanimation Clinic LTD
    Tbilisi, 0159, Georgia
  • Emergency Cardiology Center by Academician G. Chapidze LTD
    Tbilisi, 0159, Georgia
  • Tbilisi Heart and Vascular Clinic LTD
    Tbilisi, 0159, Georgia
  • Multiprofile Clinical Hospital of Tbilisi #2 LTD
    Tbilisi, 0164, Georgia
  • Charité Campus Virchow Klinikum
    Berlin, 13353, Germany
  • Städtische Kliniken Bielefeld
    Bielefeld, 33604, Germany
  • Sankt Johannes-Hospital Dortmund
    Dortmund, 44137, Germany
  • Universitätsklinikum Göttingen
    Göttingen, 37099, Germany
  • Gemeinschaftspraxis fur Kardiologie
    Heidelberg, 69115, Germany
  • Praxis Fur Innere Medizin Kardiologie, Pneumologic und Allergologie
    Mannheim, 68165, Germany
  • Universitätsmedizin Mannheim
    Mannheim, 68169, Germany
  • Barzilai Medical Center, Cardiology Dept.
    Ashkelon, 78287, Israel
  • Assaf Harofeh Medical Centre
    Be'er Ya'aqov, 70300, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 91004, Israel
  • Kaplan Medical Center
    Rehovot, 76100, Israel
  • Ziv Medical Center
    Safed, 13100, Israel
  • Tel Aviv Souraski Medical Center
    Tel Aviv, 64239, Israel
  • MULTI-MED PLUS Sp. z o.o.
    Lódz, Lodzkie 90-553, Poland
  • Niepubliczny Zakład Opieki Zdrowotnej Przychodnia Zdrowia "Zadębie"
    Skierniewice, Lodzkie 96-100, Poland
  • KO-MED Marek Konieczny
    Puławy, Lubelskie 24-100, Poland
  • Specjalistyczna Praktyka Lekarska Leszek Bryniarski
    Kraków, Malopolskie 30-082, Poland
  • NZOZ Revita Poradnia Kardiologiczna
    Kraków, Malopolskie 31-949, Poland
  • Instytut Kardiologii
    Warszawa, Mazowieckie 02-637, Poland
  • Instytut Kardiologii
    Warszawa, Mazowieckie 04-628, Poland
  • NZOZ Sródmiescie Sp z o.o.
    Gdynia, Pomorskie 81-394, Poland
  • Pomorskie Centra Kardiologiczne S.A.
    Gdansk, 80126, Poland
  • S.P. Specjalistyczny Szpital Zachodni im.JP II
    Grodzisk, Mazowiecki, 05-825, Poland
  • Krakowski Szpital Specjalistyczny im.JPII
    Krakow, 31-202, Poland
  • Synexus SCM Sp. z o.o. Oddział w Warszawie
    Warszawa, 01-192, Poland
  • Centrum Badawcze Współczenej Terapii
    Warszawa, 02-679, Poland
  • Slaskie Centrum Chorób Serca w Zabrzu
    Zabrze, 41-800, Poland
  • City Hospital #38 named after Semashko N.A
    Pushkin, St. Petersburg 196601, Russian Federation
  • Altay Regional Cardiologycal Dispensary
    Barnaul, 656055, Russian Federation
  • "Chita State Medical Academy" Curative-Diagnostic Clinic department
    Chita, 672039, Russian Federation
  • Sverdlovsky Regional Clinical Hospital of Wars Veterans
    Ekaterinburg, 620905, Russian Federation
  • Municipal Institution of Healthcare "Kemerovo Cardiology Dispensary"
    Kemerovo, 650002, Russian Federation
  • Non-state Institution of healthcare "Department hospital on station Kemerovo of OAO "Russian Railway"
    Kemerovo, 650056, Russian Federation
  • Medical centre "Delis", LLC
    Kirovsk, 187342, Russian Federation
  • Federal State Institution "National Research Center for Preventive Medicine"
    Moscow, 101990, Russian Federation
  • State healthcare institution of Moscow "City Clinical hospital#15 named after O.M.Filatov"
    Moscow, 111539, Russian Federation
  • State Healthcare institution of Moscow"Cardiology Dispensary #2"
    Moscow, 117556, Russian Federation
  • First Moscow State Medical University I.M. Sechenov
    Moscow, 119991, Russian Federation
  • State Budget Educational Institution of High Professional Education First Moscow State Medical University... #1, Cardiology Clinic, Hospital Therapy Department
    Moscow, 119991, Russian Federation
  • State Budget Educational Institution of High Professional Education First Moscow State Medical University... #1, Cardiology Clinic, Hospital Therapy Department
    Moscow, 119992, Russian Federation
  • Moscow City Clinical Hospital #51
    Moscow, 121309, Russian Federation
  • FGU Central Clinical Hospital with Polyclinic of President Administrative Department of RF
    Moscow, 121359, Russian Federation
  • Moscow State University of Medicine and Dentistry based on Moscow City Clinical Hospital #71
    Moscow, 121374, Russian Federation
  • City Clinical Hospital named after S.P.Botkin
    Moscow, 125284, Russian Federation
  • State Institution of Moscow Healthcare "City Clinical Hospital named after S.P. Botkin"
    Moscow, 125284, Russian Federation
  • Moscow State Institution of Health "City Clinical Hospital #81"
    Moscow, 127644, Russian Federation
  • Federal State Institution "Outpatient department #3" of President Management department of Russian Federation
    Moscow, 129090, Russian Federation
  • State Novosibirsk Regional Clinical Hospital
    Novosibirsk, 630087, Russian Federation
  • Regional Clinical Hospital named after N.N.Burdenko
    Penza, 440026, Russian Federation
  • State Institution of Healthcare Perm Regional Hospital for War Veterans
    Perm, 614097, Russian Federation

Showing the first 100 of 135 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Arnold SV, Kosiborod M, Li Y, Jones PG, Yue P, Belardinelli L, Spertus JA. Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial. Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):844-50. doi: 10.1161/CIRCOUTCOMES.113.000752. Epub 2014 Sep 23. PubMed 25249560 ↗
  • Roubinian NH, Escobar GJ, Liu V, Gardner MN, Carson JL, Kleinman SH, Murphy EL; NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS-III). Decreased red blood cell use and mortality in hospitalized patients. JAMA Intern Med. 2014 Aug;174(8):1405-7. doi: 10.1001/jamainternmed.2014.2889. No abstract available. PubMed 24978650 ↗
  • Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, Ben-Yehuda O, Katz A, Jones PG, Olmsted A, Belardinelli L, Chaitman BR. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013 May 21;61(20):2038-45. doi: 10.1016/j.jacc.2013.02.011. Epub 2013 Mar 10. PubMed 23500237 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 2 years 1 month after primary completion. A results delay was requested in Oct 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2011
First posted
Aug 30, 2011
Start
Sep 2011
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results delay requested
Oct 8, 2013
Results first posted
Nov 4, 2014
Last update
Nov 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01425359
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 30, 2011
Start date
Sep 2011
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Nov 4, 2014
Last update
Nov 4, 2014

Study contacts

Patrick Yue, MD
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion